Patent details

EP2426150 Title: ANTI-NKG2A ANTIBODIES AND USES THEREOF

Basic Information

Publication number:
EP2426150
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP111869012
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
ANTI-NKG2A ANTIBODIES AND USES THEREOF
French Title of Invention:
Anticorps anti-NKG2A et leurs utilisations
German Title of Invention:
Anti-NKG2A-Antikörper und deren Verwendungen
SPC Number:

Dates

Filing date:
28/06/2007
Grant date:
25/10/2017
EP Publication Date:
07/03/2012
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
25/10/2017
EP B1 Publication Date:
25/10/2017
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
28/06/2027
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
18/10/2017
 
 

Name:
Novo Nordisk A/S
Address:
Novo Allé, 2880 Bagsværd, Denmark (DK)

Agent

Name:
ARONOVA S.A.
From:
17/01/2018
Address:
PO Box 327, 4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
To:

Inventor

1

Name:
Spee, Pieter
Address:
Denmark (DK)

2

Name:
Padkjær, Søren Berg
Address:
Denmark (DK)

Priority

Priority Number:
06116429
Priority Date:
30/06/2006
Priority Country:
European Patent Office (EPO) (EP)

Classification

IPC classification:
A61K 39/395; A61P 31/12; A61P 35/00; A61P 37/00; C07K 16/28; C07K 16/46;

Publication

European Patent Bulletin

Issue number:
201743
Publication date:
25/10/2017
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
30/06/2026
Annual Fee Number:
20
Annual Fee Amount:
300 Euro
Expected Payer:
Last Annual Fee Payment Date:
23/05/2025
Last Annual Fee Paid Number:
19
Last Annual Fee Paid Amount:
281 Euro
Payer:
ANAQUA SERVICES (ANC. SGA2)
Filing date Document type Number of pages
17/01/2018 Power Of Attorney 1
31/01/2018 Outgoing Correspondence 1